Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News argenx SE ADR ARGX

Healthcare Biotechnology
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an... see more

Recent & Breaking News (NDAQ:ARGX)

argenx reports third quarter 2019 financial results and provides business update

GlobeNewswire October 24, 2019

argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference

GlobeNewswire September 3, 2019

argenx to Present at 2019 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 6, 2019

argenx reports half year 2019 financial results and second quarter business update

GlobeNewswire August 1, 2019

argenx to report half year 2019 financial results and second quarter business update on August 1, 2019

GlobeNewswire July 25, 2019

argenx announces pipeline expansion and "argenx 2021" vision to build integrated immunology company at 2019 R&D Day

GlobeNewswire May 22, 2019

argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology

GlobeNewswire February 4, 2019

argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition

GlobeNewswire November 1, 2018

argenx reports third quarter 2018 financial results and provides business update

GlobeNewswire October 24, 2018

argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology

GlobeNewswire October 8, 2018

argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody

GlobeNewswire August 22, 2018

argenx to Present at 2018 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 9, 2018

argenx receives second preclinical milestone payment under its development agreement with AbbVie

GlobeNewswire June 28, 2018

argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris

GlobeNewswire June 20, 2018

argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation

GlobeNewswire June 14, 2018

argenx selected for BEL 20 Index

GlobeNewswire June 5, 2018

argenx reports first quarter 2018 financial results and provides business update

GlobeNewswire May 9, 2018

argenx to receive third preclinical milestone payment from collaboration with LEO Pharma - Milestone associated with CTA approval for ARGX-112

GlobeNewswire April 12, 2018

argenx appoints Keith Woods as Chief Operating Officer

GlobeNewswire April 9, 2018

Earnings Scheduled For April 2, 2018

Benzinga.com  April 2, 2018